Clearside Biomedical, Inc. Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Zuprata™ in Diabetic Macular Edema
15 nov. 2016 08h23 HE
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
Alimera Sciences Proposes Public Offering of Common Stock
10 août 2016 16h01 HE
|
Alimera Sciences, Inc.
ATLANTA, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a pharmaceutical company that specializes in research, development and commercialization of...
Alimera Sciences announces clinical presentations and sponsored Symposia at ASRS 2016 Annual meeting
09 août 2016 07h30 HE
|
Alimera Sciences, Inc.
ATLANTA, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in research, development and commercialization of prescription ophthalmic pharmaceuticals, today...